User profiles for Rajen Mody

Rajen Mody

Professor of Pediatrics, Hematology/Oncology, University of Michigan
Verified email at umich.edu
Cited by 5139

Integrative clinical genomics of metastatic cancer

…, R Chugh, F Worden, MM Zalupski, J Innis, RJ Mody… - Nature, 2017 - nature.com
Metastasis is the primary cause of cancer-related deaths. Although The Cancer Genome
Atlas has sequenced primary tumour types obtained from surgical resections, much less …

Twenty-five–year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study

R Mody, S Li, DC Dover, S Sallan… - Blood, The Journal …, 2008 - ashpublications.org
Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for late effects of
cancer therapy. Five-year ALL survivors (< 21 years at diagnosis; n = 5760 eligible, 4151 …

Integrative clinical sequencing in the management of refractory or relapsed cancer in youth

RJ Mody, YM Wu, RJ Lonigro, X Cao, S Roychowdhury… - Jama, 2015 - jamanetwork.com
Importance Cancer is caused by a diverse array of somatic and germline genomic aberrations.
Advances in genomic sequencing technologies have improved the ability to detect these …

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: Phase 1 trial results

…, L Chesler, M Granger, AV Desai, R Mody… - Nature medicine, 2023 - nature.com
Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically
to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study …

XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative …

…, L Madden, BJ Kitchen, R Mody… - Blood, The Journal …, 2010 - ashpublications.org
X-linked inhibitor of apoptosis (XIAP) deficiency, caused by BIRC4 mutations, is described
to cause X-linked lymphoproliferative disease (XLP) phenotypes. However, compared with …

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised …

R Mody, A Naranjo, C Van Ryn, LY Alice… - The lancet …, 2017 - thelancet.com
Background Outcomes for children with relapsed and refractory neuroblastoma are dismal.
The combination of irinotecan and temozolomide has activity in these patients, and its …

Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia

S Ramchandren, M Leonard, RJ Mody… - Journal of the …, 2009 - Wiley Online Library
Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children. Recent
advances in treatment have led to dramatically improved survival rates. Standard ALL …

Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children's Oncology Group

R Mody, AL Yu, A Naranjo, FF Zhang… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The combination of irinotecan, temozolomide, dintuximab, and granulocyte-macrophage
colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients with …

Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways

…, NYR Agar, L Zhao, C Kumar-Sinha, R Mody… - Cancer discovery, 2023 - AACR
The clinical, radiographic, and molecular analyses included in this study demonstrate the
efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to …

Use of [18F]Fluorodeoxyglucose Positron Emission Tomography in Evaluating Locally Recurrent and Metastatic Adrenocortical Carcinoma

…, FP Worden, PG Gauger, RJ Mody… - The Journal of …, 2006 - academic.oup.com
Context: Adrenocortical carcinomas are uncommon, and their evaluation by [ 18 F]fluorodeoxyglucose
positron emission tomography (FDG PET) has not been well evaluated. Objective: …